Physician profile
Ronald W Billips
NPI 1881850592
$12,396.05
in general payments reported to CMS, 2019-2025
34 companies · $5,214 in 2025
The $5,214 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $857 · 2021: $974 · 2022: $1,254 · 2023: $1,233 · 2024: $1,604 · 2025: $5,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,243 · Long Term Medical Supply Or Device Loan: $3,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.86 |
| Long Term Medical Supply Or Device Loan | $3,808.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $3,808.00 | 2025 | Rs-Sg, Rs-4i Plus With Intersperse |
| Novo Nordisk INC | $1,137.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,021.48 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $1,006.99 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $878.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $677.35 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $662.09 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $636.37 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $373.47 | 2019-2025 | Verquvo, Belsomra |
| Pfizer INC. | $283.14 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.85 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $210.09 | 2019-2024 | |
| Mylan Specialty L.P. | $201.18 | 2022-2024 | Yupelri |
| Exact Sciences Corporation | $198.58 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $188.61 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $109.38 | 2024 | Amvuttra |
| Xeris Pharmaceuticals, INC. | $95.02 | 2023-2025 | Gvoke Hypopen |
| Vifor Pharma, INC. | $79.60 | 2019-2020 | |
| Abbott Laboratories | $68.97 | 2021-2025 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $65.24 | 2019-2021 | |
| Amarin Pharma, INC. | $55.98 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $53.02 | 2022-2023 | Quviviq |
| Dexcom, INC. | $43.88 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.70 | 2025 | Xifaxan |
| Hologic Sales and Service, LLC | $34.57 | 2023 | Aptima, Thinprep 2000 Processor |
| Phathom Pharmaceuticals, INC. | $33.38 | 2024 | Voquezna |
| Gilead Sciences, INC. | $29.23 | 2020 | |
| Verona Pharma, INC. | $24.93 | 2025 | Ohtuvayre |
| Biohaven Pharmaceuticals, INC. | $21.86 | 2021 | |
| Shield Therapeutics INC | $19.52 | 2023 | Accrufer |
| Viatris Specialty LLC | $19.26 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.65 | 2025 | Trintellix |
| Allergan, INC. | $13.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Billips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.